Investigator-initiated clinical trial to evaluate the efficacy of AMPA-PET in functional recovery process by rehabilitation for subjects registered in the clinical phase II trial of T-817MA (T817MAJP201R trial)

Takuya Takahashi0 个研究点目标入组 10 人开始时间: 2019年4月14日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Patients whose consent of participation in T817MAJP201R is confirmed in written form are judged to be eligible for the registration.
•2. Patients whose consent of participation in this trial is confirmed in written form*.
•* It is allowed for the subject whose paralysis is too severe to sign the consent form to make an observer attend in obtaining informed consent.

•1. Patients with advanced renal dysfunction in examinations within 7 days prior to enrollment (creatinine level> 1.5 mg / dL)
•2. Patients with severe liver dysfunction in examinations within 7 days prior to enrollment (AST or ALT> 150 IU / L)
•3. Patients with contraindications to MRI and AMPA-PET examinations (patients with metal in their bodies, patients with tattoos, patients with claustrophobia etc.)
•4. Patients who wish to raise their baby by 7 days after the start of the trial and after 2 days of the second AMPA-PET examination (both men and women)
•5. Other patients judged to be unsuitable for the study by the investigator
•** Use the latest test results before registration. In addition, the test results conducted in the T817MAJP201R test can also be used.

发起方

Takuya Takahashi